StemCell Therapy

SUNRISE, Fla., March 22, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT.OB - News), a company focused on developing stem cell therapies for heart disease, previously announced that they entered into an agreement with Stemlogix, LLC, a veterinary regenerative medicine company, to provide additional cellular products and services to the veterinary market. Under this agreement, the companies are offering stem cell banking for veterinary patients (pets). WPLG, channel 10 featured this exciting technology in a news segment which aired in the South Florida area. A small sample of tissue can be obtained from the animals during a routine procedure such as a spay or neuter. The stem cells are isolated and cryopreserved for future use as needed.

"We are excited to bring our expertise in stem cell therapy to the veterinary community," said Mike Tomas, Bioheart's President and CEO. "Stem cell therapies represent new opportunities for various types of patients and the ability to bank a pet's cells when they are young and healthy could be very valuable for future use."

WPLG, Channel 10 in Miami/South Florida featured this new technology in a news segment which aired March 15, 2012. Please see the link below:

http://www.local10.com/thats-life/health/Pet-stem-cells-frozen-banked-for-future-use/-/1717022/9285894/-/apcx9rz/-/index.html

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

About Stemlogix, LLC

Stemlogix is an innovative veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the best possible stem cell therapy to dogs, cats and horses at the point-of-care. Stemlogix provides veterinarians with the ability to isolate regenerative stem cells from a patient's own adipose (fat) tissue directly on-site within their own clinic or where a patient is located. Regenerative stem cells isolated from adipose tissue have been shown in studies to be effective in treating animal's suffering from osteoarthritis, joint diseases, tendon injuries, heart disorders, among other conditions. Stemlogix has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. For more information about veterinary regenerative medicine please visit http://www.stemlogix.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

More:
Bioheart Labs and Stemlogix Veterinary Products Featured in Media

This entry was posted on March 23, 2012 at 3:00 pm and is filed under Cell Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |